Not Available

Not AvailableDistinctiveness, Uniformity and Stability (DUS) testing provides rights for breeders to exploit or develop new plant varieties, to allow access to foreign varieties with widen gene pool, to promote intensive breeding activities and to prevent unauthorized varieties exploitations. In the present investigation, 41, 14, 11, 9, 50 and 40 hybrids of Cymbidium, Dendrobium, Vanda, Cattleya, Phalaenopsis and Oncidium, respectively, were studied for development of DUS test guidelines using common descriptors. In Cymbidium, out of 66 characteristics, pseudobulb size, inflorescence length, number of flowers, flower width, flower duration, flower predominant color, lip ornamentation, blooming time; in Dendrobium, among 60 characteristics, plant height, internode length and number, inflorescence length, flower width, lip colour, and ornamentation and flowering time and in Vanda, among 66 characteristics, plant type, internode length, leaf type, spike length, flower number, inflorescence colour, sepal and petal ornamentation, lip shape, colour and ornamentation, spur length and flowering time were used for grouping of hybrids. In Cattleya, among 53 common descriptors developed, plant height, leaf number/ pseudobulb, flower width in front view, petal predominant colour, lip predominant colour and lip colour pattern and in Phalaenopsis, among 58 common descriptors developed, plant size, flower width in front view, petal predominant colour and colour pattern, predominant colour and colour pattern of apical lobe of lip whereas in Oncidium among 60 common descriptors, plant type, leaf number per basal leaves /pseudobulb, flower width in front view, petal main colour, petal colour pattern, lip main colour and lip colour pattern were used for grouping of hybrids.Not Availabl

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Aims: Hypertensive disorders occur in women with peripartum cardiomyopathy (PPCM). How often hypertensive disorders co-exist, and to what extent they impact outcomes, is less clear. We describe differences in phenotype and outcomes in women with PPCM with and without hypertensive disorders during pregnancy. Methods: The European Society of Cardiology PPCM Registry enrolled women with PPCM from 2012-2018. Three groups were examined: 1) women without hypertension (‘PPCM-noHTN’); 2) women with hypertension but without pre-eclampsia (‘PPCM-HTN’); 3) women with pre-eclampsia (‘PPCM-PE’). Maternal (6-month) and neonatal outcomes were compared. Results: Of 735 women included, 452 (61.5%) had PPCM-noHTN, 99 (13.5%) had PPCM-HTN and 184 (25.0%) had PPCM-PE. Compared to women with PPCM-noHTN, women with PPCM-PE had more severe symptoms (NYHA IV in 44.4% and 29.9%, p<0.001), more frequent signs of heart failure (pulmonary rales in 70.7% and 55.4%, p=0.002), higher baseline LVEF (32.7% and 30.7%, p=0.005) and smaller left ventricular end diastolic diameter (57.4mm [±6.7] and 59.8mm [±8.1], p<0.001). There were no differences in the frequencies of death from any cause, re-hospitalization for any cause, stroke, or thromboembolic events. Compared to women with PPCM-noHTN, women with PPCM-PE had a greater likelihood of left ventricular recovery (LVEF≥50%) (adjusted OR 2.08 95% CI 1.21-3.57) and an adverse neonatal outcome (composite of termination, miscarriage, low birth weight or neonatal death) (adjusted OR 2.84 95% CI 1.66-4.87). Conclusion: Differences exist in phenotype, recovery of cardiac function and neonatal outcomes according to hypertensive status in women with PPCM